Leadless cardiac pacemaker implantation for bradyarrhythmias

implantation, and provide them with clear written information. In addition, the use of NICE's information for the public on leadless cardiac pacemaker implantation for bradyarrhythmias is recommended. 1.3 Further research in people who could have conventional cardiac pacemaker implantation should report the patient selection criteria and compare leadless pacemakers with conventional pacemakers. Follow-up should be for at least 5 years and outcomes should include adverse events, symptom relief, quality of life and device durability in the long-term. 1.4 Clinicians should enter details about all patients having leadless cardiac pacemaker implantation for bradyarrhythmias onto the National Institute for Cardiovascular Outcomes Research database and review local clinical outcomes. 1.5 The procedure should only be done in specialist centres by clinicians with specific training on, and supervised experience in, inserting the device. Centres where this procedure is done should have both cardiac and vascular surgical support for emergency treatment of complications. 1.6 NICE advises clinicians to follow the Medicines and Healthcare products Regulatory Agency's (MHRA) Expert Advisory Group recommendations on leadless cardiac pacemaker therapy. 1.7 NICE may review this procedure on publication of further evidence. 2 The condition, current treatments and procedure The condition 2.1 Bradyarrhythmias are abnormal heart rhythms that can result
